彻底改变阿尔茨海默病检测:免疫相关基因生物标志物作为非侵入性预测剂
Samin Abed1, Amir Ebrahimi1, Fatemeh Fattahi1
1Department of Genetics, Tabriz University of Medical Sciences, Tabriz, Iran.
Molecular neurobiology
|April 28, 2025
概括
研究人员在血液中确定了三种与免疫相关的基因 (IL17C,TEK,CCL4),用于早期发现阿尔茨海默氏症 (AD). 这种新的生物标志物面板显示了80.2%的准确性,为AD提供了一个有希望的非侵入性诊断方法.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 早期和非侵入性检测阿尔茨海默病 (AD) 仍然是一个重大挑战.
- 免疫系统功能障碍越来越被认为是AD病变的关键因素.
- 开发特定的生物标志物需要了解疾病的分子基础.
研究的目的:
- 确定用于早期发现阿尔茨海默病的新型,非侵入性生物标志物.
- 为了调查免疫系统功能障碍在阿尔茨海默病发展中的作用.
- 为了验证AD患者候选基因的诊断能力.
主要方法:
- 微阵列分析和权重基因共同表达网络分析 (WGCNA) 以确定差异表达基因 (DEG).
- 功能性丰富分析和与ImmPort.com的免疫相关基因进行交叉引用.
- 在AD患者中对候选基因表达的RT-PCR验证和诊断准确性的评估.
主要成果:
- 在AD患者的血液中确定了269个DEG.
- 来自WGCNA的"蓝色"模块,主要涉及免疫反应,被选择用于进一步分析.
- 在AD患者中确认IL17C,TEK和CCL4的异常表达,通过生物标志物小组实现了80.2%的诊断准确度.
结论:
- 一个由IL17C,TEK和CCL4组成的生物标志物面板证明了阿尔茨海默病检测的高精度.
- 该小组基于AD的免疫反应,提供了潜在的非侵入性诊断策略.
- 对免疫相关生物标志物的进一步研究可以显著推进早期AD诊断和治疗.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
313
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
313
Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125
